Skip to main
CSTL
CSTL logo

CSTL Stock Forecast & Price Target

CSTL Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Castle Biosciences Inc. is experiencing significant growth in its TissueCypher test, with a year-over-year increase of 92% in test volume for 2Q25 and continued momentum with a 75% growth rate in Q3. The company has also improved the gross margin for TissueCypher, achieving an impressive 77% margin, which reflects the effectiveness of its operational strategies. Additionally, with the gastrointestinal sales force expected to reach maturity in the second half of 2025, Castle Biosciences is well-positioned for sustained revenue growth in this segment.

Bears say

Castle Biosciences Inc. faces a challenging outlook primarily due to significantly lower expected EV-to-estimated revenue multiples for its dermatology and DecisionDx-UM tests compared to TissueCypher, which could impact overall revenue growth. Additionally, management acknowledged during the Q3'24 call that a lack of clinician awareness, particularly in the gastroenterology market, is a critical barrier to test adoption, indicating that penetration rates for key products may remain low. Despite indications that the stock appears undervalued based on conservative estimates, these underlying issues could hinder financial performance and investor confidence moving forward.

CSTL has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Castle Biosciences Inc (CSTL) Forecast

Analysts have given CSTL a Buy based on their latest research and market trends.

According to 6 analysts, CSTL has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Castle Biosciences Inc (CSTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.